Press Releases

Month Year

Month Year

Sep 28, 2022

Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis

Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials
Sep 8, 2022

Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis
Aug 31, 2022

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)
Aug 30, 2022

FDA grants priority review to efanesoctocog alfa for people with hemophilia A
Aug 26, 2022

Sanofi higher dose flu vaccines preferentially recommended for adults 65+ in CDC Morbidity and Mortality Weekly Report

Show per page

Print
Email page
RSS